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1. Introduction 
Alzheimer’s diseases (AD) are the most frequent dementias across the world and represent 
more than 60% of all neurodegenerative dementias including those with Lewy bodies (DLB) 
and frontotemporal lobar degeneration (FTLD). Most neurodegenerative dementias are 
induced by aggregation of different brain proteins; they are nosologically grouped into a 
large pathological entity named proteinopathy. Prevalence of dementias is more than 20% in 
85 years old aged population and linearly increases with the age (Ferri, Prince et al. 2005). 
The international impact of degenerative dementias across the world is estimated to touch 
more than 24 million patients with an incidence about 4.6 million new cases by year. 
Diagnosis of AD is still based on the integration of clinical examination, neuropsychological 
data, radiological and biological analyses. The final diagnosis is established after 
neuropathological examination of brain and observation of typical cerebral failures, in 
consequence, the clinical diagnosis is “probable AD” when typical criteria are found and 
“possible AD” if atypical elements are present during clinical examination. Nevertheless, 
the clinical diagnosis performance for “probable AD” is relatively low with a sensitivity and 
a specificity of 80% and 70% respectively (Knopman, DeKosky et al. 2001). Because a 
consequent clinical overlap does exist between etiological AD and others causes of 
dementia, the clinical diagnosis specificity for a possible AD is less than 50%. Paraclinical 
analyses such as radiological and biological examinations tend to increase accuracy of 
differential diagnoses as well as diagnosis precocity for these patients. 
2. How can we deal with the clinical diversity of Alzheimer’s phenotypes? 
AD is associated with a progressive disruption of the neuronal function and subsequent 
gradual deterioration in cognition and behaviour leading finally to the death (Khachaturian, 
1985). The typical clinical beginning of AD is characterised by a progressive cognitive 
alteration affecting predominantly episodic memory. Other symptoms such as language 
deficit, visuoperceptive alterations or even dysexecutive syndromes appear during the 
course of the disease in relation to the progression of cerebral failures into the associative 
brain areas. Decrease in episodic memory is associated with radiological finding of obvious 
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medial temporal lobe atrophy during the first step of the disease progression (Scheltens, Fox 
et al. 2002). Effectively, this cerebral structure highly participates in the memory process; 
even more, neuropathological findings demonstrated the strong implication of typical 
protein depositions met in AD that occur during this medial temporal lobe atrophy (Burton, 
Barber et al. 2009). Nevertheless, this kind of atrophy can be met in other pathologies such 
as FTLD or DLB, without any cerebral pathological hallmark of AD (O'Brien, Paling et al. 
2001; van de Pol, Hensel et al. 2006). Moreover, frequent clinical overlaps (Kertesz, 
McMonagle et al. 2005; Josephs, Petersen et al. 2006; Hort, O'Brien et al. 2010) as well as 
pathological co-occurrence (Merdes, Hansen et al. 2003; Amador-Ortiz, Lin et al. 2007; 
Schneider, Arvanitakis et al. 2009) between these 3 dementias can occur, resulting in a 
misleading clinical diagnosis during lifetime. 
During the AD progression, other symptoms than the alteration of the episodic memory 
progressively appear, but they can also be clinically predominant at the first step of the 
disease. For example, a dysexecutive syndrome, concordant with a frontal atrophy, and then 
the first hypothesis of frontotemporal dementia (FTD) diagnosis can finally be an AD. As 
well, an aphasic clinical presentation associated with temporal cerebral areas atrophy, 
suggestive of primary progressive aphasia, can reveal an etiological AD. Other clinical 
presentations can occur in the first symptoms of AD, such as apraxic forms suggesting 
corticobasal degeneration (CBD) or even visual deficits associated with posterior cortical 
atrophy (PCA). 
These focal presentations of AD are clinically difficult to distinguish from other previously 
adverted neurodegenerative dementias which typically begin with these kind of clinical 
features (Alladi, Xuereb et al. 2007). It is why there is a need to identify inside this spectrum 
focal presentations underlying AD as well as other pathologic processes such as FTLD or 
DLB. 
3. Neuropathological hallmark and physiopathological pathways of AD 
The two neuropathological hallmarks of AD are the deposition of extracellular amyloid 
plaques and accumulation of intracellular neurofibrillary tangles (NFT). The first ones are 
principally constituted by amyloid protein  (Aß peptide), a product of proteolytic processing 
by secretases of the amyloid precursor protein named APP (Haass and Selkoe 1993), and the 
second involves phosphorylated tau protein (Masters, Simms et al. 1985; Braak and Braak 
1991). Distributions of amyloid plaques and NFTs do not overlap in all anatomical regions 
suggesting a complex pathogenetic scenario.  
Tau protein is a microtubule associated protein expressed abundantly in the neuronal axons 
that promotes assembly and stability of microtubules. 6 different isoforms of tau are present 
in the human brain, constituted of 352 to 441 amino acids and harbouring more than 70 
phosphorylation sites (Buée, Bussiere et al. 2000; Lewczuk, Esselmann et al. 2004). Its 
physiological function is regulated by these phosphorylations (Johnson and Hartigan 1999). 
The abnormal hyperphosphorylation of tau proteins in AD brain reduces their biological 
activity and results in disintegration of the microtubules (Uversky, Winter et al. 1998). 
Moreover, this phenomenon induces conformational changes of tau protein and then 
permits its assembly in paired helical filaments (PHF), the major constituent of NFTs (Kidd 
1963; Alonso, Zaidi et al. 2001). These PHF are highly phosphorylated since more than 30 
phosphorylation sites were observed in PHF deriving from NFTs (Liu, Liang et al. 2006). 
The stereotypic development of tau pathology with NFTs is clearly correlated with clinical 
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impairment of memory, starting in the transentorhinal cortex to finally involve associative 
areas and the whole neocortical areas (Braak and Braak 1995; Berg, McKeel et al. 1998). 
In an other scheme, Aß  depositions neither correlate with a given clinical presentation and 
seem to begin in the neocortex before involving the neuronal projections of already involved 
areas (Arriagada, Growdon et al. 1992). These amyloid plaques are also encountered in 
asymptomatic aged peoples without AD (Wolf, Gearing et al. 1999). Furthermore, metabolic 
imaging and particularly positron emission tomography with 11C-PIB (a compound that 
specifically stain amyloid plaques) demonstrate that these amyloid accumulations are 
observed in subjects without any cognitive alteration (Villemagne, Fodero-Tavoletti et al. 
2008). Although numerous proteins are associated with amyloid deposits in AD (Buée, Hof 
et al. 1992; Uchihara, Duyckaerts et al. 1996; Burns, Noble et al. 2003), the major 
proteinaceous component is the 42 amino acid Aß peptide (Aß42) which is the most 
hydrophobic form of Aß (Jarrett, Berger et al. 1993; Gravina, Ho et al. 1995). Nevertheless, it 
was recently demonstrated that aggregation into amyloid plaques may provide truncated 
forms of this peptide in the N-terminal (Aß4-/5-/8-/9-42) during the first steps of the disease 
(Sergeant, Bombois et al. 2003; Vanderstichele, De Meyer et al. 2005). These truncated forms 
could represent more than 60% of all cerebral Aß forms (Sergeant, Bombois et al. 2003). 
Interestingly, the symptomatology observed in AD (or other neurodegenerative dementia) 
seems not due to these deposits and symptoms could appear before protein aggregations 
(Moechars, Dewachter et al. 1999). Several in vitro studies demonstrated that the toxicity 
against neurons is related to oligomeric forms of proteins and that the consequence is 
cognitive alteration in animal models (Kirkitadze, Bitan et al. 2002; Cleary, Walsh et al. 2005; 
Lesne, Koh et al. 2006). For AD, soluble oligomeric forms have been described, aggregating 
later on into amyloid plaques and it was suggested that effects of these oligomeric species 
could induce the first toxic events of amyloidopathy (Simmons, May et al. 1994; Kirkitadze, 
Condron et al. 2001; Walsh and Selkoe 2007). 
Some controversy still remains on the course and distribution pattern of the Aß and tau 
pathologies. Some authors suggest that amyloid dysfunction is the pathogenic key leading 
to AD pathogenesis. This hypothesis was developed as “amyloid cascade” and the Aß 
metabolism dysfunction may initiate others pathologic events such as tau protein 
hyperphosphorylation, synaptic loss or neuroinflammation (Hardy and Higgins 1992; 
Hardy and Selkoe 2002). Nevertheless this hypothesis is still discussed and does not support 
all the AD physiopathology. 
During the preclinical phase of AD, the neuronal degeneration proceeds and at a certain, yet 
unidentified, threshold the first symptoms appear. Otherwise, it seems that first cerebral 
failures begin several decades before symptoms appear (Braak and Braak 1997). 
Nevertheless the early and differential diagnosis remains difficult and reliable proof of AD 
process is difficult to obtain. An early and reliable diagnosis in order to establish 
appropriate drug treatment is essential to decrease symptomatology. Moreover, since 
research is conducted to develop treatments that could retard or stop cerebral failure 
progression, we need to improve AD diagnosis to identify this process before brain damages 
are too significant. 
4. Which CSF biochemical markers might allow us to detect Alzheimer’s 
diseases? 
It is convincing that we could identify these neurodegenerative processes early during the 
course of AD with the help of paraclinical means such as functional imaging or use of 
biological markers.  
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An ideal biomarker for Alzheimer disease would have to meet three specific criteria: 
- To be a quantitative and objective measure providing an indication of disease risk and 
rate of disease progression long before onset of symptoms 
- To be reliable, reproducible and inexpensive to measure 
- To be measurable in an easily accessible tissue of the patient.  
During the past years, great efforts have been made to identify reliable biomarkers for AD in 
body fluids of patients that are suitable for minimal invasive early diagnosis of AD, mainly 
cerebrospinal fluid (CSF) and blood. Cerebrospinal fluid (CSF) closely reflects the 
composition of the brain extracellular space and is likely to have the highest yield in 
biomarkers (Wiltfang, Lewczuk et al. 2005). Furthermore, CSF biological modifications seem 
to appear before first anatomical modifications seen on magnetic resonance imaging 
(Schoonenboom, van der Flier et al. 2008). Nevertheless, lumbar puncture is relatively 
invasive even if complications appear in less than 2% of patients (Blennow, Wallin et al. 
1993). So research strives for a less invasive biological diagnosis with development of blood 
markers for AD. 
A high number of CSF brain-derived proteins have been investigated as potential markers 
for AD. The more promising are proteins resulting from cerebral failures meet in AD: tau 
proteins with total tau (T-tau), phosphorylated tau proteins (P-tau) and Aß42 which are 
solubles in CSF. Moreover, AD diagnosis criteria were reviewed for research in 2007 and 
these 3 biomarkers were included (Dubois, Feldman et al. 2007). 
- Aß peptide 
In AD patients the CSF concentration of soluble Aß42 decreases and it has been suggested 
that this may be due to the preferential deposition of Aß peptides into cerebral amyloid 
plaques reflecting parenchymental sequestration with lower levels diffusing to CSF 
(Strozyk, Blennow et al. 2003; Wiltfang, Lewczuk et al. 2005; Fagan, Mintun et al. 2006). 
Interestingly, this CSF concentration is linked to ApoE genotype which was identified as a 
susceptibility gene to develop AD: patients with homozygote genotype of ApoE4  have 
lower Aß42 CSF concentration (Galasko, Chang et al. 1998). Nevertheless, a CSF Aß42 
concentration decrease is also observed in other pathologies such as DLB or even 
Creutzfeldt Jakob disease (CJD), pathology with sometimes cerebral Aß deposits 
(Andreasen, Minthon et al. 2001; Wiltfang, Esselmann et al. 2003; Mollenhauer, Bibl et al. 
2005). These results are in accordance with pathological overlaps observed in these diseases 
(Schneider, Arvanitakis et al. 2007; Schneider, Arvanitakis et al. 2009; Kovacs, Seguin et al. 
2011). Nonetheless, measurement of CSF Aß42 concentration could differentiate AD patients 
from subjects without any neurodegenerative process with sensitivity and specificity of 86% 
and about 90% respectively (Blennow 2004). ELISA measurement of CSF Aß42 reveals values 
comprised between 600 and 1230 pg/mL in normal subjects and 260 and 500 pg/mL in AD 
patients (Riemenschneider, Lautenschlager et al. 2002; Riemenschneider, Wagenpfeil et al. 
2002; Lewczuk, Esselmann et al. 2004). 
Several works postulate that Aß aggregates will be more reliable biomarkers than soluble 
Aß forms, as the aggregates are directly involved in the pathologic events of AD. 
Monoclonal and polyclonal antibodies specific to soluble oligomeric forms of Aß were 
developed (Kayed et al, 2010, Ying Z et al, 2009)  and used to demonstrate that these 
oligomers are significantly more abundant in the soluble brain extracts of AD patients (Meli 
et al., 2009) suggesting that diffusible oligomers would also appear in the CSF. Sensitive 
techniques were applied to detect CSF Aß oligomers in AD patients (Pitschke, Prior et al. 
1998). Recently, a study showed that levels of CSF aggregated Aß forms are higher in AD 
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patients than in patients with other neurological disorders without neurodegenerative 
processes (Fukumoto, Tokuda et al. 2010). Moreover, the CSF oligomer concentrations 
correlate with cognitive alteration in AD. While detection of these CSF oligomeric forms 
appears to have a considerable diagnosis interest, low concentrations of these pathologic 
forms do not allow considering this assay routinely?. 
In parallel to Aß42, numerous N- and C- terminal truncated forms have been identified in 
clinical samples from AD patients (Gabelle, Roche et al. 2010). Most abundant Aß peptides 
in CSF are, in increasing order concentrations, Aß40, Aß38 and Aß42 (Wiltfang, Esselmann et 
al. 2002). Concentration measurements of the major form Aß40 in CSF are greatly instructive 
because they well reflect total amount of Aß peptide release in this biological fluid 
(Wiltfang, Esselmann et al. 2007). By the APP metabolism and the amyloidogenic way, 
strong cerebral producers of Aß peptides have higher Aß CSF levels (and thus also Aß42) 
than weak producers. Instauration of Aß40 CSF measurements associated with Aß42 could 
permit to rectify mistakes in interpretation of biological results with CSF Aß42 levels alone. 
In addition to CSF Aß40, Aß38 and Aß42, other forms of this peptide are produced by 
physiological regulation of Ǆ-secretase (Gabelle, Roche et al. 2010). Numerous both cerebral 
and CSF truncated forms of Aß peptide were identified in AD and MCI patients using 
immunobloting or mass spectrometry analyses (such as SELDI-TOF) (Lewczuk, Esselmann 
et al. 2003; Sergeant, Bombois et al. 2003; Vanderstichele, De Meyer et al. 2005). Part of 
research concentrates on identification of novel Aß truncated forms that could allow better 
predictive power and specificity of biological diagnosis (Bibl, Mollenhauer et al. 2007). 
Indeed, new Aß13, Aß14 or else Aß16 peptides were described within CSF of AD patients and 
surprisingly Aß16 CSF levels increase in AD patients (Portelius, Zetterberg et al. 2006). 
Identification of these Aß fragments in the CSF could lead to a more specific differential 
diagnosis since it may exist distinct CSF Aß fragment profiles between AD, DLB or FTD, 
these profiles could reflect distinct physiopathological events between these pathologies 
(Bibl, Mollenhauer et al. 2007). So, the use of these new biomarkers could lead to novel 
diagnostics and therapeutics approaches for Alzheimer’s diseases. 
- Tau proteins 
Increase of T-tau CSF levels was found in AD patients as well as MCI patients who will 
develop later an AD (Riemenschneider, Buch et al. 1996; Andreasen, Minthon et al. 2001; 
Riemenschneider, Lautenschlager et al. 2002; Hansson, Zetterberg et al. 2006). Measurement 
of T-tau levels with ELISA test (Innotest hTau Ag, Innogenetics) reveal concentrations 
between 150 pg/mL and 450 pg/mL in control subjects and between 300 and 1100 pg/mL in 
AD patients (Riemenschneider, Lautenschlager et al. 2002; Lewczuk, Esselmann et al. 2004; 
Grossman, Farmer et al. 2005). Nevertheless, increase of T-tau CSF levels is not AD specific 
since it is also observed in different concentrations in CJD or even an acute stroke (Otto, 
Wiltfang et al. 1997; Hesse, Rosengren et al. 2000). T-tau CSF levels in patients with sporadic 
CJD are higher than those observed in patients with other neurodegenerative dementias 
including AD (Otto, Wiltfang et al. 1997; Otto, Wiltfang et al. 2002). Threshold for CSF T-tau 
concentration in sporadic CJD was determined at 1300pg/mL in 2002 in a study conducted 
on 300 patients with CJD with 109 neuropathological confirmations (Otto, Wiltfang et al. 
2002). In other forms of CJD as new variant, CSF T-tau levels are lower than those observed 
in sporadic disease (Sanchez-Juan, Green et al. 2006).Thus, T-tau is more a neuronal death 
marker than a specific AD biomarker. Several diseases are neuropathologically linked to tau 
dysfunction such as in some FTD, progressive supranuclear palsy (PSP) and CBD. 
Numerous studies have investigated measurement of CSF T-tau levels in FTD but results are 
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in accordance with pathological heterogeneity of FTD (neuropathological tau inclusions or 
without tau inclusions) since existence of discordance between studies with increase of CSF 
T-tau levels or not (Riemenschneider, Wagenpfeil et al. 2002; Pijnenburg, Schoonenboom et 
al. 2004; Grossman, Farmer et al. 2005). Any biological argument does exist with T-tau CSF 
levels in pathologies like FTD or other tauopathies as PSP and CBD (Urakami, Wada et al. 
2001). Interestingly, a distinct profile of T-tau in electrophoretic separation was observed in 
CSF of sporadic CJD patients in a very recent study (Chen, Shi et al. 2010). 
More interestingly, some modifications as truncated forms can be identified on tau proteins. 
A recent study permitted to demonstrate differences in CSF levels of truncated forms of tau 
in PSP patients compared with other neurodegenerative diseases (FTD, CBD, AD, DLB and 
Parkinson disease) or control subjects (Borroni, Gardoni et al. 2009). Other proteolytic 
processes on tau protein can occur in neurodegenerative disorders and could be identified. 
CSF P-tau level specifically increase in AD patients compared with those with FTD, vascular 
dementia or control subjects (Hampel, Buerger et al. 2004). Regarding DLB, results are more 
conflicting with studies describing increase of P-tau CSF levels and others reporting normal 
concentrations (Vanmechelen, Vanderstichele et al. 2000; Parnetti, Lanari et al. 2001). So, an 
increase in P-tau CSF levels is observed in AD and MCI patients (Itoh, Arai et al. 2001; 
Andreasen, Vanmechelen et al. 2003; Herukka, Hallikainen et al. 2005). Moreover, cognitive 
decline is correlated with CSF increasing levels of P-tau, these CSF tau species might 
specifically mark a cerebral degenerative process (Maccioni, Lavados et al. 2006; Wallin, 
Blennow et al. 2006). While other P-tau species have been measured, only CSF levels of tau 
proteins phosphorylated at serine 181 (P-tau181) or threonine 231 (P-tau231) seem to clearly 
improve the accuracy of the diagnostic of AD (Buerger, Zinkowski et al. 2002; Hampel and 
Teipel 2004; Mitchell 2009). Some phosphorylations are more specific for AD, CSF P-tau181 
significantly increases in AD patients compared to patients without neurodegenerative 
processes as well as patients with other neurodegenerative dementias (Vanmechelen, 
Vanderstichele et al. 2000; Vanderstichele, De Vreese et al. 2006). The P-tau181 assay in CSF 
is now routinely used for biological differential diagnosis between AD and other forms of 
dementias. ELISA measurements of this protein (Innotest phospho-tau(181P), Innogenetics) 
reveal CSF levels between 30 pg/mL and 50 pg/mL in control subjects and between 75 
pg/mL and 100 pg/mL in AD patients (Lewczuk, Esselmann et al. 2004). This 
phosphorylated form of tau protein permits to distinguish an AD from all other 
neurodegenerative etiologies with great sensitivity and specificity (Hampel, Buerger et al. 
2004). P-tau181 CSF measurement is able to differentiate AD patients from FTD patients with 
a sensitivity of 85% and a specificity more than 80% (Schoonenboom, Pijnenburg et al. 2004). 
These results are similar in differentiation of AD and all other neurodegenerative dementias 
(Hampel, Buerger et al. 2004). Furthermore this measurement improves distinction of AD 
and DLB patients (Parnetti, Lanari et al. 2001; Vanderstichele, De Vreese et al. 2006). 
Other phosphorylated species of tau protein allow to improve accuracy of biological 
diagnosis. The P-tau231 appears early during AD pathogenesis (Augustinack, Schneider et al. 
2002). This form of tau in CSF differentiates patients with AD from control subject with high 
sensitivity and specificity (more than 90%) (Mitchell 2009), nevertheless its interest for 
differential diagnosis appears to be less important than P-tau181 except for distinction of AD 
and FTD (Hampel, Buerger et al. 2004). Moreover P-tau231 well reflects AD neuropathology 
because its CSF concentration is correlated with amounts of NFT found at the autopsy 
(Buerger, Ewers et al. 2006). Since this form of phosphorylated tau permits to identify AD 
within a population of patients presenting a mild cognitive impairement (MCI), it seems 
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particularly interesting for the early diagnosis (Brys, Pirraglia et al. 2009). The CSF P-tau231 l 
levels decrease with time during the AD process; this will enable to approach dementia 
severity (Hampel, Buerger et al. 2001). CSF P-tau199 measurement and determination of its 
phosphorylation, that seems precociously involved during AD pathogenesis and NFT 
formation (Maurage, Sergeant et al. 2003), are able to discriminate AD patients from other 
degenerative dementias with a sensitivity and a specificity of 85% and 80% respectively 
(Itoh, Arai et al. 2001). Phosphorylation of tau protein on both amino acid 231 and 235 might 
be predictive of MCI conversion into AD (Arai, Ishiguro et al. 2000). In the same way, CSF 
level of P-tau396/404 is elevated in AD compared to vascular dementia, and control subjects 
(Hu, He et al. 2002). Nevertheless these results have to be confirmed on patients with other 
degenerative disorders. 
- Combination of etiological markers 
The use of combinations of these CSF markers (Aǃ42, T-tau and P-tau181) improves biological 
diagnosis performance for dementias in terms of differential or early diagnosis (Andreasen, 
Minthon et al. 2001; Riemenschneider, Wagenpfeil et al. 2002; Pijnenburg, Schoonenboom et 
al. 2004). These CSF biomarkers are also prognosis markers since a recent prospective study 
conduct on 150 AD patients for 5 years revealed that extreme CSF biomarkers levels (high T-
tau and P-tau181 and low Aǃ42) are associated with more aggressive diseases leading to an 
earlier death (Wallin, Blennow et al. 2010). 
Recently, a clinical study of the Alzheimer Disease Neuroimaging Initiative Project has 
detected an Alzheimer disease signature in the CSF levels of, Aß42 T-tau and P-tau181 in 
more than one third of cognitively normal subjects (De Meyer, Shapiro et al. 2010). This 
finding suggests that this CSF signature is present and detectable early during the 
neurodegenerative process. A recent study including 43 patients with a clinical dementia 
disorder and conducted in Sweden failed to show a concordance between T-tau and Aß CSF 
levels and pathological symptoms (Brunnstrom, Rawshani et al. 2010). Further, it has been 
suggested that low CSF Aß42 may also be a marker of diffuse plaques in addition to fibrillar 
plaques. Indeed, Fagan and colleagues have studied the relationship between in vivo brain 
amyloid and CSF markers of proteins (T-tau, P-tau181 and Aß42) in cognitively normal 
individuals ranging in age from 43-89 years (Fagan, Mintun et al. 2009). In this study they 
have identified a new class of non demented individuals who present low CSF Aß42 with 
cerebral amyloid deposition. The authors suggested that CSF Aß42 drop prior to amyloid 
becomes detectable and may reflect the presence of diffuse plaques and/or oligomeric Aß 
species.  These data demonstrate that CSF Aß42 may be considered as a biomarker for plaque 
burden and prognosis providing the very earliest clue to identify preclinical AD. 
Combination of CSF T-tau and Aǃ42 allows to distinguish AD from FTD patients with both 
sensitivity and specificity of 85% (Riemenschneider, Wagenpfeil et al. 2002). Moreover the 
use of this combination permits to identify AD in MCI patients with sensitivity and 
specificity of 95% and 83% respectively (Hansson, Zetterberg et al. 2006). Interestingly, 
predictive value of P-tau181 is better than T-tau for prediction of conversion of MCI in AD 
patients (Parnetti, Lanari et al. 2006). Association of 3 biomarkers is clearly useful to identify 
a degenerative process concordant with AD in atypical clinical presentation. A study with 9 
patients presenting PCA revealed CSF levels of these 3 biomarkers similar to those observed 
in AD (Baumann, Duyar et al. 2010). In the same way, very recent prospective study 
conducted on 22 ACP patients demonstrated that a majority of patients with this syndrome 
(90%) have intrathecal biomarker levels compatible with AD (Seguin, Formaglio et al. in 
press). 
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Using of ratio T-tau/Aǃ42 increases the diagnosis specificity of AD compared with control 
subjects and other degenerative dementias (Gomez-Tortosa, Gonzalo et al. 2003; Kapaki, 
Paraskevas et al. 2003). Specificity of this ratio in differentiation of AD from vascular 
dementias is higher than 80% nevertheless this ratio is less efficient for differentiating AD 
and DLB (Gomez-Tortosa, Gonzalo et al. 2003). Finally, ratio T-tau/Aǃ42 could be early 
instructive since its increase permits to predict cognitive alterations in asymptomatic 
subjects within 8 years (Fagan, Roe et al. 2007). Similarly, the ratio P-tau181/Aǃ42 appears as 
an important element for differential diagnosis. It allows to distinguish AD patients from 
those with FTD with a sensitivity and a specificity of more than 90% (de Souza, Lamari et al. 
2010). Furthermore this ratio is able to discriminate patients with semantic dementia from 
AD patients with an excellent sensitivity of 98% and a specificity of 84%. Ratios with other 
forms of Aǃ peptides such as Aǃ42/Aǃ38 and Aǃ42/Aǃ37 combined with T-tau CSF levels are 
able to differentiate AD from DLB with a sensitivity of 100% and a specificity of 92% (Bibl, 
Mollenhauer et al. 2006). 
Since CSF T-tau levels in sporadic CJD are clearly elevated comparing to all other 
neurodegenerative disorders and P-tau181 is in normal concentrations, the use of P-tau181/T-
tau ratio seems interesting to identify CJD patients (Riemenschneider, Wagenpfeil et al. 
2003). This ratio is inferior to 0.05 in CJD and superior to 1.25 in AD even in very early 
stages of the disease. Similar results were found with P-tau231/T-tau (Buerger, Otto et al. 
2006). It is important to note that CSF P-tau181 level in new variant CJD are higher than in 
sporadic CJD, and this inversely to T-tau CSF level (Goodall, Head et al. 2006). So, this ratio 
P-tau181/T-tau is able to differentiate sporadic CJD from new variant with an elevated ratio. 
Nevertheless, biological levels overlap, particularly between new variant CJD and AD, thus 
does not permit to attain a differential diagnosis value. 
Other combinations with different P-tau are useful for biological diagnosis. Combining CSF 
P-tau181 and P-tau231 enables to identify AD patients with a sensitivity of 94%, but a weak 
specificity of 66% confronting with all neurodegenerative disorders (Hampel, Buerger et al. 
2004). More interestingly, ratio of P-tau396/404 and T-tau is able to distinguish AD patients 
from others dementias with a sensitivity and a specificity of 96% and 86% respectively and 
have an excellent specificity (100%) in the distinction of AD and vascular dementias (Hu, He 
et al. 2002). 
- Others potential biological markers 
Numerous other molecules have been investigated as biological CSF markers and are liable 
to participate on etiological dementia diagnosis. We briefly deal with some of them which 
seem to supply advantage for differential and early diagnosis. 
Implication of oxidative stress hypothesis and inflammation in AD or other 
neurodegenerative disorders opened some research ways. It is known that inflammation is 
associated with parenchymal Aß deposits in AD (Schmidt, Schmidt et al. 2002). 
Inflammation markers have been investigated in CSF to reveal potential inflammatory 
process linked to these pathological deposits. Inflammatory mediators such as chemokines 
might be increased into AD patients CSF (Galimberti, Schoonenboom et al. 2006; Galimberti, 
Schoonenboom et al. 2006). The concentration of classical complement cascade C1q subunit 
decreases in CSF of AD patients and is correlated with disease severity (Smyth, Cribbs et al. 
1994). However, this intrathecal molecule only attests for microglial reactions met in AD and 
also during physiological aging (Lue, Walker et al. 2001; Schuitemaker, van der Doef et al. 
2011). Similarly isoprostane CSF levels, an oxidative stress marker, clearly increase in 
biological fluid (CSF, blood and urine) proportionally to cognitive decline and might be an 
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early biomarker of AD in MCI patients (Pratico, Clark et al. 2000; Pratico, Clark et al. 2002). 
If these molecules seem interesting for understanding physiopathological mechanisms 
which occur in neurodegenerative disorders (oxidative stress and microglial activation 
particularly), these biomarkers cannot be a specific part of differential diagnosis since they 
are frequently involved during cerebral aging (Montine, Peskind et al. 2011). 
Molecules with an implication in protein catabolism are present within CSF and their levels 
may reflect cerebral damages. An increase of the intrathecal neprisylin activity was 
observed and correlated to T-tau CSF level and cognitive decline in AD patients and patient 
with prodromal form of AD (Maruyama, Higuchi et al. 2005). Nevertheless this activity is 
modestly predictive for MCI conversion to dementia. Ubiquitine, another catabolic signal 
protein might be linked to aggregated tau proteins in the cerebral cortex and its CSF levels 
might increase in AD patients (Iqbal, Flory et al. 2005). Moreover ubiquitine CSF levels 
correlate with those linked with cerebral tau aggregates in AD (Kudo, Iqbal et al. 1994). 
Nevertheless, elevated ubiquitine CSF levels were observed in other non-AD dementias 
(Iqbal and Grundke-Iqbal 1997). 
A protein largely present in CSF and blood, tranthyretin, has higher CSF levels in AD and 
MCI stage. CSF measurements can distinguish AD from control subjects with sensitivity of 
100% and specificity of 93% (Lovell, Lynn et al. 2008). In the same way, CSF concentrations 
of the mitochondrial protein cytochrome c are increased in AD and permit to identify AD 
process in MCI patients with a sensitivity of 100% and specificity of 75% (Papaliagkas, 
Anogianakis et al. 2009). However, a specificity problem is present regarding other 
neurodegenerative dementia such as FTD (Ruetschi, Zetterberg et al. 2005). 
Recently, Zhong and colleagues have quantified the levels and the activity in the CSF of ß-
secretase (BACE 1), an enzyme involved in the cleavage of APP to Aß (Zhong, Ewers et al. 
2007). An elevated BACE 1 activity was observed in CSF of MCI and AD subjects compared 
with normal controls. Moreover, this activity was correlated with CSF BACE 1 protein and 
Aß peptide levels. A more recent study showed that CSF BACE1 activity correlates with CSF 
Aß40, total T-tau and P-tau181 levels but surprisingly not with intrathecal Aß42 concentration 
(Mulder, van der Flier et al. 2010). These results are promising and suggest that BACE 1 
could be a potential candidate as a biomarker of early-stage AD, but additional studies are 
necessary to confirm this hypothesis. 
4. Peripheral biomarkers 
Because the CSF collection by lumbar puncture is an invasive, expensive and time-
consuming procedure, the detection of biomarker molecules in blood would be more widely 
applicable. However, in comparison with CSF biomarkers, efforts to discover reliable 
biomarkers for Alzheimer’s disease in peripheral blood have not been successful and do not 
allow developing a solid diagnostic. The use of many different sensitive ELISA tests for the 
detection of  and  allowed the detection and quantification of Aß in human plasma 
(for review see Irizarry, 2004; Mehta, 2007). According to these studies, some controversy 
persists concerning the changes in blood Aß levels in relation with the severity of the disease 
suggesting that plasma Aß levels cannot allow differentiating sporadic AD from control 
cases. As the pool of circulating Aß includes multiple C-terminal truncated fragments, and 
possibly oligomeric species, it has been suggested that the use of of antibodies to various 
forms of Aß with different affinities may explain these differences. Nevertheless, the ELISA 
assay may not be an ideal method to measure Aǃ levels in blood. Indeed, the two major 
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difficulties in the measurement of Aǃ in plasma consist in the low concentration of the 
plasma peptide, needing a more sensitive quantification assay, and in the interaction of the 
beta peptide with different carrier proteins present in plasma, that can mask the epitopes of 
Aǃ and interfere with the detection of the peptide (Kuo et al., 2000).  
Nowadays, the development of more sensitive and more specific assays for the detection of 
plasma Aǃ levels is needed for proposing plasma Aǃ as a biomarker for diagnosis. To 
overcome the Aǃ low levels different new promising strategies have been developed based 
on purification and concentration steps prior to the Aǃ peptides analysis. Using a 
denaturing solid-phase extraction (SPE) combined with an ELISA assay, Lanz and co-
workers (Lanz & Schachter, 2008) have compared the Aǃ detection in plasma and CSF bio-
fluids of normal individuals. But, while human CSF exhibit, in comparison with non-SPE 
samples, the most robust recovery (≥ 90%), the human plasma showed a lower recovery 
(between 40 and 60% in function of the extraction process used, guanidine or acid formic, 
respectively) suggesting that the use of a SPE step does not improve the detection of the 
protein comparatively to the non-denatured plasma. Slemmon and collaborators (Slemmon 
et al., 2007) have linked to the SPE a reverse-phase HPLC (SPE-HPLC) compatible with 
analysis by ELISA. In this study, the detection of Aǃ peptides from the whole blood of six 
normal subjects was analyzed; by comparison with a native plasma, a significantly increase 
in the amount of total Aǃ peptide was obtained after guanidine extraction  and HPLC 
detection, with concentrations ranging from 100 to 165pg/ml. These results suggest that 
there is a pool of Aǃ peptides in non-denatured plasma samples that is not accessible for the 
detection by ELISA assay probably due to their interactions with plasma proteins or to their 
aggregated state that could mask the epitopes. 
Several studies on the detection of tau proteins in blood have been performed but failed to 
show a clear relationship to dementia diagnosis, thus, the correlation between increased tau 
brain levels and elevated CSF levels of tau in AD patients is not totally clear (Bitsch et al., 
2002; Ingelson et al., 1999). Further research is needed to improve the specificity and the 
sensitivity of the assay in order to develop a robust method to measure tau protein levels in 
serum or plasma. 
Recently, various plasma signalling proteins were proposed as potential candidates to 
develop a blood test for AD (Ray et al., 2007). O’Bryant and colleagues developed an 
algorithm in order to differentiate patients with Alzheimer disease from controls. In this 
study serum protein-based multiplex biomarker data from a large group of Alzheimer 
patients and controls were analyzed. Combined with age, sex, years of education and ApoE 
genotype, their logarithm model reached a diagnostic sensitivity and specificity of 94% and 
84% respectively (O’Bryant et al., 2010). 
In addition to CSF and blood, several other biological fluids are under investigation for the 
detection of AD biomarkers. Among these biological fluids, a special attention is accorded to 
saliva and urine. The study of Bermejo and colleagues (Bermejo-Pareja et al., 2010) found 
that saliva Aǃ42 is, in comparison with control subjects, significantly elevated in early stage 
AD patients while  levels remain unchanged within all the samples analyzed. Curiously 
the elevated saliva Aǃ42 levels were not observed in severe stages of the disease. This 
augmentation seems to be specific to AD and not to Parkinson disease.  These results show 
that in combination with Aǃ levels in brain, the saliva levels of Aǃ42 could be a potential 
biomarker for clinical AD.  
In addition to the specific markers of AD disease (like Aǃ peptides and tau proteins), there 
are non-specific markers like oxidative stress and neuronal inflammation molecules. An 
increased expression in AD patients of many inflammatory and pro-inflammatory cytokines 
has been widely documented. Inflammation in AD brains induces important microglia 
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activation and consequently production of free radicals responsible of an intense oxidative 
stress. So these inflammatory and oxidative mechanisms are involved in the aetiology of AD 
and can contribute to the neurodegeneration. However conflicting results exist about the 
pertinence of the use of these peripheral biomarkers. Among the inflammatory markers 
several cytokines have been measured in CSF or blood, such as interleukin 1- and 1-ǃ, 
interleukin-6, -10, -11 and -18, and tumor necrosis factor-alpha (for review see Casoli et al., 
2010; Olson & Humpel, 2010). But the results are very divergent between the different 
groups. The same conclusions can be enunciated for chemokines. More studies are needed 
to clarify and determine the reproducibility of such inflammatory markers.  
Oxidative stress parameters have also been investigated as AD biomarker. A biomarker of 
oxidative stress study (BOSS) coordinated by the NIH was performed in order to determine 
among 16 commonly studied biochemical products of oxidative stress which ones could 
been validated as in vivo biomarkers (kadiiska et al., 2005). This study was performed on 
plasma, blood and urine samples. Among these molecules, malondialdehyde (MDA), 8-
hydroxy-2′-deoxyguanosine (8-OHdG) and F2-isopropanes were the most promising 
biomarkers of oxidative stress. F2-isopropanes, a product of lipid peroxidation, was the 
most extensively investigated in CSF of AD patients. These clinical studies showed 
comparatively with control subjects a significant increase of F2-isopropanes in damaged 
regions of AD brain and in CSF in patients in early stages of mild cognitive dementia 
(Montine et al., 1999, 2001; Pratico et al., 2000). In plasma and urine samples, the 
quantification of such marker yield to conflicting results.  
5. Which techniques could be applied? 
Hyperphosphorylated Tau proteins are currently used for AD diagnostics in CSF, as 
recently proposed by an international working group on Alzheimer Disease (NINCDS-
ADRA working group) (Dubois et al., 2007). Moreover, there are no well-established and 
accepted biochemical tests available for therapeutic follow-up of these diseases. Their 
diagnosis requires thus high sensitivity and specificity. Sensitivity is needed for early 
diagnosis, when the biomarker is present at very low levels to ensure cost-effective 
therapeutic interventions before the disease has progressed to a stage where damages to the 
brain are irreversible. Specificity is needed to discriminate first, non-degenerative causes of 
dementia (e.g. vascular, alcoholic, psychiatric, metabolic, infective etc.) from degenerative 
forms and, second, to discriminate the different molecular aetiologies in order to propose an 
appropriate therapeutic treatment: for example, anticholinesterase drugs show certain 
efficacy in AD, but not in frontotemporal dementia (Musial et al., 2007). 
Today, AD can be diagnosed with certainty only post-mortem with histopathological 
evaluation of amyloid plaques and NFTs. Ante-mortem, AD is diagnosed by clinical criteria. 
Clinical diagnosis included systematically before 2007 December the presence of dementia 
(McKhann et al., 1984). Before apparition of dementia symptoms, complaining patients 
suffer from memory trouble without social and professional effects; this clinical phase was 
usually called “amnestic mild cognitive impairment (MCI)” (Petersen et al., 1999). Many of 
these patients convert to AD whereas few of them convert to other neurodegenerative 
dementia or remain stable (Fischer et al., 2007). As recently proposed, using the combination 
of clinical, neuropsychological, imaging methods and CSF biomarkers, this clinical stage 
would be nowadays called preclinical AD and, more important, its detection would allow a 
better care for AD patients. Neuropsychological evaluation permits a more accurately 
defined diagnosis, but it is time consuming (half a day), is not available for all concerned 
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people, is still proposed at advanced stages of disease, and is not 100% accurate since there 
is a risk of overlaps among different aetiologies of dementia as frontotemporal degeneration 
(FTD), Lewy’s body dementia (LBD), and potentially other dementias. Neuroimaging may 
permit exclusion of vascular pathology, detection of hippocampal atrophy and cerebral 
hypoperfusion (Tapiola et al., 2008; Xu et al., 2007). It must be noted that first AD lesions 
may coexist with vascular dementia in at least 50 % of cases. During the past years, great 
efforts have been made to identify reliable biomarkers for AD in body fluids of patients that 
are suitable for minimal invasive early diagnosis of AD, mainly cerebrospinal fluid (CSF) 
and blood. Recently, we’ve summarized all of the criteria needed to establish convenient 
technique with the following advantages (Dupiereux et al. (2009): 
a. Low-cost 
b. Rapid-fast 
c. Good level of accuracy 
6. Should Alzheimer’s detection be associated to biomarkers of other 
diseases? 
Other diseases could be associated with AD resulting in mixed dementias. Furthermore, 
unique pathologies could mimic others and it is difficult to make differences between given 
pathological events or to identify all neurodegenerative processes. Effectively, 15 to 50% of 
AD patients have Lewy bodies (neuropathological hallmark of DLB constituted by ǂ-
synuclein) associated with NFT and Aǃ deposits after neuropathological examination 
(Hamilton 2000). Nevertheless, ǂ-synuclein (ǂ-Syn) is not always associated with this 
clinical phenotype (Parkkinen, Kauppinen et al. 2005). This pathological association seems 
to make part for cognitive alteration severity with a synergic effect (Clinton, Blurton-Jones et 
al. 2010). Mixed dementia may be more aggressive than pure AD (Kraybill, Larson et al. 
2005). Since a low CSF ǂ-Syn level was detected in CSF of patients with DLB and Parkinson 
disease comparing to other neurodegenerative diseases, an association of this measurement 
with typical CSF biomarkers of AD seems interesting (Tokuda, Salem et al. 2006; Kasuga, 
Tokutake et al. 2010). Moreover, oligomeric forms of ǂ-Syn were detected in CSF and blood 
of patients with Parkinson disease (El-Agnaf, Salem et al. 2006). Nevertheless, several 
studies are conflicting since elevated or normal CSF levels were also observed in DLB 
patients (Mukaetova-Ladinska, Milne et al. 2008; Spies, Melis et al. 2009; Ballard, Jones et al. 
2010). In the same way, we can postulate an association of typical CSF biomarkers of AD 
with prion CSF measurement since neuropathology of CJD is more intricate than we though 
it several years ago (Kovacs, Seguin et al. 2011). 
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